Comparing the current results to its competitors, Innate Pharma Sa reported Revenue decrease in the 4 quarter 2025 year on year by -55.25 %, despite the revenue increase by the most of its competitors of 17.21 %, recorded in the same quarter.
Innate Pharma Sa's Comment on Competition and Industry Peers
The company operates in the immuno-oncology and anti-cancer therapy market, which is characterized by rapid technological advancements and significant competition. Competitors include major pharmaceutical companies, specialty pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and public and private research organizations. Specifically, other companies developing antibody-drug conjugates (ADCs) targeting Nectin-4 include Eli Lilly, Astellas Pharma, and Corbus Pharmaceuticals. These competitors often possess greater resources and experience in research, drug development, finance, manufacturing, marketing, technology, personnel, and patient access for clinical studies. The company's products face competition from existing and future therapies, and earlier market entry, lower pricing, broader therapeutic coverage, or superior efficacy or tolerability by competitors could negatively impact the company's business and financial results.
Sab Biotherapeutics Inc's business model focuses on developing and producing innovative antibody therapeutics using advanced genetic engineering techniques.
Recursion Pharmaceuticals Inc is a biotech company that utilizes its artificial intelligence (AI) platform to identify and develop potential drug candidates. They employ a unique approach by combining AI technology with experimental biology and automation to accelerate drug discovery. Recursion applies its platform to identify new treatments for rare diseases and have established partnerships with various organizations in the pharmaceutical industry.
Sources:
Innate Pharma Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Innate Pharma Sa versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
